Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiocyanic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL17474635 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Acetonitrile SCHEMBL318491 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Acetonitrile SCHEMBL29256909 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL31139173 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL5512184 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL4069335 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL1160667 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL214962 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL5350 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA | |
| Water SCHEMBL16460263 | 0.89 | GAA (0.59) | ALDH1A1MAPTTDP1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113384567-B | Preparation method and application of euphorbia lathyris alkyl type macrocyclic diterpenoid compounds | 广州中大南沙科技创新产业园有限公司 | 2022-07-19 | — | — | CN | claimed |
| WO-2023025225-A1 | CYCLIN K DEGRADATION AGENT | 杭州阿诺生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| CN-111848640-B | Elephantopus scaber lactone compound, preparation method and application thereof | 中国医学科学院药用植物研究所 | 2022-10-28 | — | — | CN | disclosed |
| CN-113461704-B | Monoterpene coumarin compound, preparation method and application thereof | 中国医学科学院药用植物研究所 | 2022-07-26 | — | — | CN | disclosed |
| CN-112675170-B | Application of V027-0576 in preparation of antitumor drugs | 南华大学附属第一医院 | 2022-02-01 | — | — | CN | disclosed |
| EP-3911331-A1 | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150210-A1 | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
| US-20180055899-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Cartilage Disorders, or Both | UNIGEN, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| CN-105793253-A | Autotaxin inhibitor compounds | 法玛克亚公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105764903-A | Tetracyclic autotaxin inhibitors | 法玛克亚公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | disclosed |
| US-7153883-B2 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GPI NIL HOLDINGS INC. (US) | 2006-12-26 | — | — | US | disclosed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | disclosed |
| US-20030186961-A1 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GUILFORD PHARMACEUTICALS | 2003-10-02 | — | — | US | disclosed |
| US-4076918-A | CELLULOSE REACTED WITH THIOCYANIC ACID | ARGUS CHEMICAL CORPORATION (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055899-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Cartilage Disorders, or Both | VDR, CYP24A1, HPGDS | ALDH1A1 3605/4885MAPT 4413/4885TDP1 4367/4885 |
| US-20030186961-A1 | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | BDNF, NGF, HCAR2 | ALDH1A1 437/4885MAPT 118/4885TDP1 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.